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Abstract
Neural control of vascular tone is important for the maintenance of circu-
latory homeostasis. Neurogenic vascular relaxation is obtained not only 
by the inhibition of constrictor nerves, but also by the stimulation of dila-
tor nerves. We have reported that the vasodilator nerve innervating the 
cerebral artery is nitrergic in nature. In anesthetized animals, electrical 
stimulation (ES) of a pterygopalatine ganglion (PPG) or a greater petrosal 
nerve (GPN) only dilated cerebral arteries on the stimulated side. Nitric 
oxide (NO) synthase inhibitors abolished this dilation. Surgical denerva-
tion at the PPG instantly produced cerebroarterial constriction. In rats, ES 
of the nerve bundles from the PPG significantly increased cerebral blood 
flow, which was inhibited by NO synthase inhibitors. After systemic infu-
sion of FITC (fluorescence)-dextran (10 kD) in anesthetized dogs, ES was 
applied to one side of the PPG. The fluorescent intensity in certain areas 
of the brain was higher on the stimulated side. Similar findings were 
obtained histochemically. T1-weighted MRI enhanced by gadolinium-DTPA 
during the GPN-stimulation in monkeys showed higher signal intensities 
in certain brain regions on the stimulated side. These findings suggest 
that nitrergic nerves tonically dilate the cerebral artery to maintain the 
cerebral circulation and may play a role in the regulation of blood–brain 
barrier permeability. [Tzu Chi Med J 2009;21(1):1–5]
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1. Cerebroarterial dilation and increase 
in cerebral blood flow (CBF)
1.1.  Discovery of nitrergic nerves
The role of the autonomic nervous system in the circu-
lation of the brain was once thought to be less im-
portant than in other organs. The contraction of the 
cerebral artery caused by sympathetic nerve activation 
is weaker than that of other arteries. Furthermore, the 
role of the parasympathetic nerve innervating blood 
vessels including the cerebral artery was thought to 
be negligible.
Toda first found that isolated cerebral arteries re-
sponded to transmural electrical stimulation (TES) 
with relaxation, which is resistant to both beta-blockers 
and atropine [1]. The relaxation caused by TES was 
independent of the absence of endothelium, resistant 
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to several receptor antagonists and desensitized to 
several peptides, but was abolished by treatment with 
nitric oxide (NO) synthase inhibitor(s), restored by the 
addition of L-arginine, and abolished by treatment 
with tetrodotoxin. Furthermore, a histochemical study 
demonstrated that the neuronal type of NO synthase 
(nNOS)-containing nerve fibers were mainly in the 
adventitial layer of the cerebral artery. The results also 
showed that nerve stimulation by electrical pulses 
increased the release of NOX (nitrate and nitrite) from 
the endothelium-denuded cerebral artery and the con-
tent of cyclic GMP in this artery. These findings led us 
to consider that the vasodilating neurotransmitter of 
the cerebral artery was unstable NO itself or stable 
NO analog(s).
We performed experiments to examine whether 
the neurotransmitter was NO itself or instead stable 
analogs of NO such as S-nitrosocysteine, dinitrosyl-iron-
cysteine complex, nitroxyl and hydroxylamine [2]. Iso-
lated cerebral arteries without the endothelium after 
treatment with diethyldithiocarbamic acid, an inhibi-
tor of copper/zinc superoxide dismutase, responded 
to TES with relaxation that was markedly inhibited 
by treatment with duroquinone, a superoxide anion-
generating agent. The inhibition was partially reversed 
by exogenously applied superoxide dismutase. These 
findings suggest that the neurotransmitter liberated 
from vasodilator nerves innervating cerebral arteries 
was NO itself rather than stable analogs of NO [3]. 
Therefore, we concluded that the vasodilator trans-
mitter released from nerves innervating the cerebral 
artery was actually NO in several animal models [4], 
including dogs [5] and monkeys [6].
1.2. Anatomy of nitrergic nerves 
innervating the cerebral artery
Ethanol was injected into the vicinity of one side of the 
pterygopalatine ganglion (PPG) in dogs to chemically 
degenerate the PPG. After 1 week of injections, isolated 
middle cerebral artery (MCA) and posterior cerebral 
artery (PCA) strips from both sides (impaired and in-
tact sides) were transmurally stimulated. The changes 
in tension were examined. The MCA and PCA on the 
intact side were relaxed by the stimulation, which was 
abolished by treatment with NO synthase inhibitors, 
whereas stimulation failed to relax the arteries on the 
impaired side. Furthermore, positive NADPH diapho-
rase staining of perivascular nerves was found in the 
MCA and PCA on the intact side, but not on the im-
paired side [7]. This enzyme in the neuronal tissues is 
thought to be identical to nNOS [8]. Thus we thought 
that the nitrergic nerves innervating the cerebral arter-
ies originated from the PPG. Another histochemical 
study also demonstrated that the PPG was the major 
source of positive fibers in the cerebral arteries [9].
1.3. Studies with cerebral angiography
In anesthetized dogs [10] and monkeys [11], the ap-
plication of electrical stimulation (ES) to one side of 
the PPG or to the greater petrosal nerve (GPN), which 
is the preganglionic nerve of PPG, dilated cerebral ar-
teries only on the stimulated side, as observed using 
cerebral angiography. NO synthase inhibitors abolished 
this dilation. Systemic treatment with hexamethonium, 
a ganglionic blocking agent, abolished the vasodila-
tion caused by GPN stimulation, but failed to affect the 
dilation caused by PPG stimulation. Surgical denerva-
tion of the postganglionic nerve from the PPG in dogs 
instantly produced cerebroarterial constriction [10]. 
These findings suggest that impulses possibly from the 
superior salivary nucleus located at the midbrain that 
run through the GPN and nerve terminals of the GPN 
release acetylcholine (ACh). The released ACh binds to 
and activates nicotinic receptors on the dendrites or the 
cell bodies of nitrergic nerves in the PPG. We also 
suggest that nitrergic nerves tonically dilate cerebral 
arteries.
1.4. Measurement of CBF
In rats chronically treated with capsaicin to denervate 
the sensory nerves, application of ES to one side of 
the nerve bundles derived from the PPG significantly 
increased the CBF on the stimulated side, as assessed 
using a laser-Doppler flowmeter. NO synthase inhibi-
tors dose-dependently inhibited the increase in CBF 
and the addition of L-arginine restored the CBF [12].
1.5. Summary
GPN, one of the parasympathetic efferent nerves, is 
derived from the brain stem and forms synapses at 
the PPG. Nitrergic nerves, postganglionic nerves from 
the PPG, innervate cerebral arteries and participate 
in the physiological regulation of the vascular tone 
and blood flow in the brain [13].
2. Possible opening of the blood–brain 
barrier (BBB)
2.1. The BBB
The BBB is the major defense mechanism of the 
brain and regulates the entry of substances from the 
blood into the nerve cells of the brain. Generally, 
molecules larger than 0.5 kDa or hydrophilic sub-
stances cannot freely cross the BBB. However, it has 
been shown that the defense mechanisms of the brain 
impair the access of therapeutic drugs to focal brain 
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lesions (inflammation, neoplasm and degenerative 
diseases).
2.2. Studies with fluorescence 
measurements
Recently, Yarnitsky et al reported that stimulation of 
the PPG produces a transient increase in the vascu-
lar permeability of the BBB in the rat brain [14]. To 
confirm this finding in medium-sized animals, we col-
laborated with their group in experiments on dogs. In 
anesthetized dogs, FITC (fluorescent marker)-dextran 
(10 kDa) was systemically infused and ES was applied 
to one side of the PPG. The fluorescent intensity in cer-
tain brain areas (frontal lobe, olfactory bulbs, striatum, 
hypothalamus and hippocampus), which were irrigated 
by arteries innervated by nitrergic nerves derived from 
the PPG, was higher on the stimulated side of the brain 
than that on the non-stimulated side [15]. In contrast, 
the fluorescent intensity in the cerebellum and pons, 
which were irrigated by arteries innervated by nitrergic 
nerves that originated from a place other than the 
PPG, was not affected by the stimulation. Results of 
histochemical studies support these findings.
2.3. MRI study
To further investigate the effects of PPG activation on 
the BBB function, we performed an MRI study in mon-
keys. T1-weighted MRI enhanced by gadolinium-DTPA, 
a non-ionic contrast agent, usually enhances proton 
signaling in regions with very slow blood flow (cavern-
ous sinus, choroid plexus, cerebral arteriovenous mal-
formation, etc.) [16] or with impaired BBB function 
(tumor, inflammation, etc.). The MRI study performed 
during unilateral GPN-stimulation in monkeys demon-
strated higher signal intensities in the temporal lobe, 
striatum and hippocampus on the stimulated side. A 
midline shift, suggestive of unilateral brain edema, was 
not observed. Thus we found that stimulation of mon-
key GPN elicits excitation of nitrergic nerves derived 
from the PPG innervating the cerebral artery, dilates 
the arteries, and may increase BBB permeability.
3. Clinical aspects
3.1. Cerebral infarction
As described above, CBF may, at least in part, be con-
trolled by NO released from nitrergic nerves innervat-
ing the cerebral artery, indicating that dysfunction of 
the nitrergic nerves may induce cerebral ischemia and 
then lead to infarction. Koketsu et al [17] measured the 
infarct sizes following MCA occlusion in spontaneous 
hypertensive rats after parasympathetic denervation. 
The volume of the infarction was larger after selective 
sectioning of parasympathetic nerves containing ni-
trergic nerves derived from the PPG, suggesting that 
dysfunction of nitrergic nerves may exacerbate cere-
bral ischemia. A significant increase in the infarct 
size developed by the treatment with a NO synthase 
inhibitor in rats after occlusion of MCA, and additional 
intravenous injection of L-arginine decreased the in-
farct volume [18]. Therefore, it seems that NO released 
from nitrergic nerves innervating cerebral arteries pro-
tects the brain from cerebral ischemia and infarction. 
Thus stimulation of the PPG may minimize the size 
of lesions in cerebral ischemia and infarction.
3.2. Cerebral vasospasm after subarachnoid 
hemorrhage
Delayed cerebral vasospasm after subarachnoid hem-
orrhage (SAH) produces severe neurological deficits 
or death of patients if successful treatment is not 
performed for ruptured intracranial aneurysm. In ex-
perimental animals, including dogs and monkeys, 
two injections of autologous blood into the cisterna 
magna induced delayed vasospasm, as seen in hu-
mans [19]. The injections of oxyhemoglobin into the 
cisterna magna induces vasospasm in a few hours 
[20], whereas injection of a NO synthase inhibitor pro-
duces vasoconstriction within 1 hour and additional 
injection of L-arginine restores the constriction [21,22]. 
NO synthase inhibitors act more potently on the nerve 
than on the endothelium. Oxyhemoglobin is well 
known as a strong scavenger of NO. Thus deletion of 
the nerve-derived NO by oxyhemoglobin metabolized 
from hemoglobin after SAH may initiate the delayed 
vasospasm. Recently, subacute sodium nitrite infu-
sions were reported to prevent delayed cerebral vaso-
spasm in a primate model of SAH [23]. Therefore, 
stimulation of nitrergic nerves may prevent delayed 
cerebral vasospasm after SAH.
3.3. Migraine and cluster headaches
The clinical effectiveness in patients with headaches 
of ergotamine, flunarizine, a Ca2+ channel blocker, 
and serotonin 5-HT1 agonists, including sumatriptan, 
which constrict intra- and extra-cranial arteries, are 
well recognized. However, the etiology of migraines 
and cluster headaches has yet to be clarified. The hy-
pothesis has long been proposed that dilation of cere-
bral arteries is related to vascular headaches. It has 
been reported that NO donors, such as nitroglycerin, 
produce vascular headaches [24], and NO synthase 
inhibitors prevent the headaches [25]. These findings 
support the hypothesis that endogenous NO may 
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participate in the etiology of migraines and cluster 
headaches.
Sumatriptan antagonized the NO-mediated vasodi-
lator response to nerve stimulation in cerebral arteries 
in dogs [26]. Flunarizine seems to inhibit the synthe-
sis and release of NO by reducing Ca2+ influx [27]. 
Sanders and Zuurmond reported that radiofrequency 
lesioning in the PPG was effective in 61% of patients 
suffering from cluster headaches, which did not re-
spond to therapy with medication [28]. Therefore, NO 
derived from nitrergic nerves may also be involved in 
the vascular mechanism of headaches [29].
3.4. New possibilities of selective drug 
delivery to the brain
Unwanted effects usually emerge during chemother-
apy because the BBB impairs the access of drugs to 
focal brain legions (inflammation, neoplasm, etc.), 
which results in need for relatively high dose of drugs 
compared with that for the therapy of other organs. 
Both Yarnitsky et al and our group reported that large 
molecule substances may cross the BBB during PPG 
stimulation, possibly via transient disruption of the 
BBB [14,15].
These findings lead us to investigate a novel drug-
delivery procedure that could save patients with the 
fewer doses of drugs than usual, when stimulation of 
the PPG is safely and appropriately applied to the pa-
tients with focal brain inflammation and neoplasm. 
This procedure may also be applied during immune 
therapy for patients with neurodegenerative diseases.
4. Conclusion
We conclude that nitrergic nerves, postganglionic 
nerves of the PPG, tonically dilate the cerebral arteries 
and maintain the cerebral circulation. Furthermore, 
the nitrergic nerves appear to regulate permeability of 
the BBB. Studies on nitrergic nerve function are ex-
pected to help alleviate patient suffering from several 
diseases in the brain.
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